Artelo Biosciences Surges 325% on Glaucoma Study Breakthrough

Artelo Biosciences stock has skyrocketed following the announcement of a fully-funded clinical study to test its synthetic cannabinoid compound ART27.13 in glaucoma patients. The study, backed by Glaucoma UK and the UK's HSC R&D Division, triggered a massive rally that saw shares jump over 40% in pre-market trading on March 18, 2026, with gains continuing through the week. Read more about this...